Glucowear: A non-invasive, wearable, real time continuous blood glucose monitoring sensor

Glucowear：一种非侵入式、可穿戴式、实时连续血糖监测传感器

• 批准号: 10068829
• 金额: $ 263.91万
• 依托单位: AFON TECHNOLOGY LTD
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10068829
• 关键词: Glucowear; non; invasive; wearable; real

A non-invasive, real-time BG sensor, utilising shifts in radio-wave frequency that correlate to changes in BG concentration, with a personalised algorithm for each individual trained using day 1 data. The device will be a wearable sensor designed to fit on the underside of a watch strap and compatible with iOS, android smart watches and phones. The sensor will take real time measurements, connected via Bluetooth to a phone/watch where the app will provide alerts to the user and if required, physicians/carers in real time. Battery life of 10-14 days and shelf life of at least 2 years. POC clinical trial completed in 2020, results show tracking of BG comparable to the market leader and included algorithm training. Device is now at TRL6, with components integrated into ‘first-pass’ of wearable design and in-house developmental testing conducted, including subjects tested in non-clinical environments and further algorithm building. V3 is in development. Robust patent portfolio.

一种非侵入式实时BG传感器，利用与BG浓度变化相关的无线电波频率的变化，并使用第1天数据为每个个体训练个性化算法。这款设备将是一款可穿戴式传感器，可以安装在表带下方，与iOS、安卓智能手表和手机兼容。传感器将进行实时测量，通过蓝牙连接到手机/手表上，应用程序将向用户提供警报，如果需要，还会实时通知医生/护理人员。电池寿命10-14天，保质期至少2年。POC临床试验于2020年完成，结果显示BG跟踪与市场领先者相当，并包含算法训练。该设备目前处于TRL6阶段，其组件已集成到可穿戴设计的“第一关”中，并进行了内部开发测试，包括在非临床环境中测试受试者和进一步的算法构建。V3正在开发中。强大的专利组合。